CDTX vs. AVRO, GNTA, ENTX, ALGS, LENZ, TSBX, QNCX, IKNA, OKYO, and ELUT
Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include AVROBIO (AVRO), Genenta Science (GNTA), Entera Bio (ENTX), Aligos Therapeutics (ALGS), LENZ Therapeutics (LENZ), Turnstone Biologics (TSBX), Quince Therapeutics (QNCX), Ikena Oncology (IKNA), OKYO Pharma (OKYO), and Elutia (ELUT). These companies are all part of the "biological products, except diagnostic" industry.
AVROBIO (NASDAQ:AVRO) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.
AVROBIO has higher earnings, but lower revenue than Cidara Therapeutics. AVROBIO is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.
AVROBIO has a net margin of 0.00% compared to AVROBIO's net margin of -33.19%. Cidara Therapeutics' return on equity of -74.86% beat AVROBIO's return on equity.
AVROBIO presently has a consensus price target of $2.00, indicating a potential upside of 62.60%. Cidara Therapeutics has a consensus price target of $71.25, indicating a potential upside of 461.91%. Given AVROBIO's stronger consensus rating and higher possible upside, analysts plainly believe Cidara Therapeutics is more favorable than AVROBIO.
62.6% of AVROBIO shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 9.2% of AVROBIO shares are owned by insiders. Comparatively, 7.4% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
AVROBIO has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
Cidara Therapeutics received 266 more outperform votes than AVROBIO when rated by MarketBeat users. Likewise, 70.19% of users gave Cidara Therapeutics an outperform vote while only 66.93% of users gave AVROBIO an outperform vote.
In the previous week, Cidara Therapeutics had 14 more articles in the media than AVROBIO. MarketBeat recorded 14 mentions for Cidara Therapeutics and 0 mentions for AVROBIO. AVROBIO's average media sentiment score of 0.49 beat Cidara Therapeutics' score of 0.00 indicating that Cidara Therapeutics is being referred to more favorably in the news media.
Summary
Cidara Therapeutics beats AVROBIO on 11 of the 18 factors compared between the two stocks.
Get Cidara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cidara Therapeutics Competitors List
Related Companies and Tools
